Vor Biopharma (VOR)

Executive Summary

Vor Biopharma is a clinical-stage biotechnology company focused on developing transformative therapies for autoimmune diseases, with its lead asset telitacicept (a dual BAFF/APRIL inhibitor) advancing in Phase 3 trials across multiple indications. The company is currently evaluating telitacicept in generalized myasthenia gravis (gMG) and primary Sjögren's disease, both of which are actively recruiting. Vor Bio previously terminated several oncology programs (e.g., VCAR33 and VOR33 in acute myeloid leukemia) to concentrate resources on its autoimmune pipeline, reflecting a strategic pivot to higher-value, less competitive indications. With a market capitalization of approximately $783 million, Vor Bio is positioned as a pure-play autoimmune biotech with a promising late-stage asset.

Upcoming Catalysts (preview)

• Q1 2027Telitacicept Phase 3 gMG Interim Data Readout60% success
• Q2 2027Telitacicept Phase 3 Sjögren's Disease Enrollment Completion75% success
• TBDPotential Strategic Partnership or Licensing Deal for Telitacicept50% success